First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children
A malaria vaccine, deployed in combination with current malaria-control tools, could play an important role in future control and eventual elimination of malaria in Africa. This article, published in the New England Journal of Medicine (NEJM), reports the initial results of an ongoing Phase 3 trial of RTS,S/AS01 being conducted at 11 centers in 7 African countries. The study found that the RTS,S/AS01 candidate malaria vaccine reduced clinical episodes of malaria and severe malaria by approximately half during the 12 months after vaccination in children 5 to 17 months of age. The abstract of this article is available through the NEJM by clicking on "Visit web page" below, or for free access to the full lenth article please visit malariavaccine.org and click on "Read the NEJM article."
Author(s): The RTS,S Clinical Trials Partnership
View web page (English)
(Located at www.nejm.org)
Citation: The RTS,S Clinical Trials Partnership. First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children. New England Journal of Medicine. 2011.